Goodwin Procter LLP advised Surface Oncology on the deal. Surface Oncology (Nasdaq: SURF) announced its agreement with GSK to exclusively license worldwide development and commercial rights…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
